Once-daily triple hormone receptor drug (NN1706) reduces body weight in rodents, monkeys, and humans

Declaration of competing interest Brian Finan: Shareholder and employee of Eli Lilly; shareholder and former employee of Novo Nordisk A/S Jonathan D. Douros: Shareholder and former employee of Novo Nordisk A/S Ronald Goldwater: Employee of Parexel International Ann Maria Kruse Hansen: Shareholder and employee of Novo Nordisk A/S Julie B. Hjerpsted: Shareholder and employee of Novo Nordisk A/S Karina Rahr Hjøllund: Shareholder and employee of Novo Nordisk A/S Martin K. Kankam: Employee at Altasciences Clinical Kansas, Inc., which has received research funding from Novo Nordisk A/S, Merck, Vertex, Camino, Ionis, EncuraGen Inc., Eliem Therapeutics, Arthrosi Therapeutic, Staidson Biopharma, NIAID/NIH, Amgen and Biogen Patrick J. Knerr: Shareholder and former employee of Novo Nordisk A/S Anish Konkar: Shareholder and employee of AstraZeneca Stephanie A. Mowery: Shareholder and former employee of Novo Nordisk A/S Timo D. Müller: receives research funding from Novo Nordisk and has received speaking fees from Eli Lilly, AstraZeneca, Novo Nordisk and Merck John Rømer Nielsen: Shareholder and employee Novo Nordisk A/S Sune Boris Nygård: Shareholder and employee Novo Nordisk A/S Diego Perez-Tilve: Received research funds from Novo Nordisk A/S Kirsten Raun: Shareholder and employee of Novo Nordisk A/S Bin Yang: Employee of Dexatide LLC; shareholder and former employee of Novo Nordisk A/S Matthias H. Tschöp: Advisory board of ERX Pharmaceuticals, Inc., Cambridge, MA (2019), Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation (2017–2019), research funding from Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019), consultations for Böhringer Ingelheim Pharma GmbH & Co. KG (2020 & 2021), scientific lectures for Sanofi-Aventis Deutschland GmbH (2020) and Astra-Zeneca GmbH (2024); As CEO and CSO of Helmholtz Munich, co-responsible for collaborations of the employees with a multitude of companies and institutions worldwide, including but not limited to Boehringer Ingelheim, Novo Nordisk A/S, Roche Diagnostics, Arbormed, Eli Lilly, SCG Cell Therapy and others, and overall responsible for commercial technology transfer activities. Richard D. DiMarchi: Shareholder and former employee of Novo Nordisk A/S; Co-inventor of intellectual property at Indiana University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.